| abstract |
The invention relates to antagonists of β-catenin for use in the prevention and/or treatment of neurodegenerative disorders. β-catenin has been found to specifically accumulate in Huntington's disease and this accumulation is toxic in striatal neuron expressing mutant huntingtin, the causal protein of Huntington's disease. Since β-catenin had been previously reported to accumulate in Alzheimer's disease, interfering with β-catenin accumulation in neuronal cells provides a therapeutic approach for the prevention and/or treatment of neurodegenerative disorders. |